Clinical Trial Update: A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer [Phase 4]

View source ↗

Summary

Phase 4 study evaluating enzalutamide after abiraterone treatment in metastatic castration-resistant prostate cancer has completed and posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 4 | Status: COMPLETED | Results posted: 2017-06-08